Company News

2023-09-26
The top medical Journal ‘Frontiers in Oncology’ published the preclinical study results of ImmuneOnco’s drug candidate IMM40H
On September 26, 2023,the R&D team of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) reported the preclinical research results of IMM40H under the tittle of ‘The Novel High-Affinity Humanized Antibody IMM40H Targets CD70, Eliminates Tumors Via Fc-mediated Effector Functions, and Interrupts CD70/CD27 Signaling’in the top journal Frontiers in Oncology’
View more
2023-09-13
ImmuneOnco published the preclinical research results of IMM47 in the journal "Antibody Therapeutics"
Recently, the R&D team of ImmuneOnco (Hong Kong Stock Exchange stock code: 01541.HK) reports the preclinical research results of IMM47 under the tittle of IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy " in the journal "Antibody Therapeutics".
View more
2023-09-11
ImmuneOnco completed IMM27M Phase I dose escalation and determined recommended Phase II dose
On September 11, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that IMM27M, an independently developed ADCC-enhanced CTLA-4 antibody, completed the phase I dose escalation patient enrollment and determined the recommended phase II dose.
View more
2023-09-11
IMM2510 of ImmuneOnco completed Phase I dose escalation and determined recommended phase II dose
On September 11, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that IMM2510, a PD-L1/vEGF bispecific fusion protein independently developed by ImmuneOnco, completed Phase I dose escalation and determined the recommended Phase II dose.
View more
2023-09-05
ImmuneOnco Listed on the Main Board of the HKEX
(Hong Kong, September 5th, 2023) ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (stock code: 01541.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).
View more
2023-04-07
ImmuneOnco Biopharmaceuticals Named to KPMG China's "2nd Annual Biotechnology Innovation Top 50 Companies List"
On April 7, 2023, KPMG China's "2nd Biotechnology Innovation Top 50" award ceremony was held simultaneously in Beijing, Shanghai and Shenzhen, and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was
View more
Total 55 12345678910
0.091336s